Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Ouvert

13.23 2.32

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.67

Max

13.47

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+141.78% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-161M 1.2B
Ouverture précédente	10.91
Clôture précédente	13.23

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juil. 2026, 23:56 UTC

eBay Inc. shares are trading lower in after-market hours, with no specific company news identified. The stock remains near the midpoint of its one-month trading range.

27 juil. 2026, 23:56 UTC

Steel Dynamics Inc shares are trading lower in after-market hours. No specific company news was identified to explain the price movement.

27 juil. 2026, 23:56 UTC

Alibaba Group Holding Ltd shows a slight gain in after-market trading, reflecting positive market sentiment. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

PepsiCo Inc. shares remained roughly flat during after-market hours, trading within a narrow range around the middle of their one-month range.

27 juil. 2026, 23:56 UTC

Monday.Com Ltd. shares are lower in after-market trading, fluctuating within a narrow range without specific news driving the decline.

27 juil. 2026, 23:56 UTC

Correlated Moves

Kulicke and Soffa Industries shares declined in after-market trading, reflecting broader weakness in the semiconductor sector and a drop in the Nasdaq 100 Index.

27 juil. 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

27 juil. 2026, 23:56 UTC

Correlated Moves

News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

27 juil. 2026, 23:56 UTC

Under Armour Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

Whirlpool Corp shares are higher in after-market hours, reflecting a modest increase since Monday's close amid positive sentiment in European markets.

27 juil. 2026, 23:56 UTC

Archer-Daniels-Midland Co is rising in after-market trading, reversing three sessions of declines. No specific news was identified to explain this movement.

27 juil. 2026, 23:56 UTC

Matador Resources Co shares are higher in after-market trading following Monday's close, despite remaining below their 20-day moving average.

27 juil. 2026, 23:56 UTC

JD.Com Inc. shares declined in after-market trading, despite a strong one-month gain and trading above its 20-day moving average. No specific news was identified.

27 juil. 2026, 23:56 UTC

Correlated Moves

Costco shares are lower in after-market trading, following a slight decline in the Nasdaq 100 Index. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

Social Media

General Motors plans a $6 billion investment in U.S. manufacturing, including an expansion at its Orion Township plant. Shares are roughly flat in after-market trading.

27 juil. 2026, 23:56 UTC

Shell PLC shares showed little change in after-market trading. The stock remains above its 20-day moving average amid positive sentiment in European markets.

27 juil. 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

27 juil. 2026, 23:56 UTC

Trimble Inc shares are lower in after-market hours following Monday's close. The stock remains above its 20-day moving average despite the decline.

27 juil. 2026, 23:52 UTC

Mexico's Business Confidence Data Release on August 3, 2026, Expected to Reflect Cautious Sentiment Amid Global Market Volatility and Inflationary Pressures.

27 juil. 2026, 23:52 UTC

U.S. Initial Jobless Claims Expected at 204,000 Amid Positive Labor Market Sentiment and Fed Policy Speculation

27 juil. 2026, 23:52 UTC

Australia's Building Permits Expected to Decline by 0.5% in June Amidst Ongoing Weakness in Housing Construction and Elevated Borrowing Costs

27 juil. 2026, 23:52 UTC

Weis Markets shares declined after-market, remaining about 4.47% below their 20-day moving average. No specific news was identified to explain the movement.

27 juil. 2026, 23:52 UTC

Xylem Inc shares are higher in after-market trading, continuing a trend of four consecutive sessions of gains and remaining above the 20-day moving average.

27 juil. 2026, 23:51 UTC

Trustmark Corp shares are higher during after-market hours, moving from a low of -0.04% to a high of 0.95% since Monday's close.

27 juil. 2026, 23:51 UTC

Correlated Moves

Vanguard Total Bond Market ETF trades higher after-market, reflecting broader market trends amid easing geopolitical tensions and a drop in oil prices.

27 juil. 2026, 23:51 UTC

J B Hunt Transport Services Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the movement.

27 juil. 2026, 23:51 UTC

Social Media

Correlated Moves

Shares lower in after-market trading; call writer profits $1.28 million.

27 juil. 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

27 juil. 2026, 23:51 UTC

News

Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

27 juil. 2026, 23:51 UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

141.78% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 141.78%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.